地塞米松对中重度急性呼吸窘迫综合征合并COVID-19患者存活且无通气天数的影响:CoDEX随机临床试验
CoDEX是一项在巴西41个ICU开展的多中心、随机、开放标签临床试验,纳入299例COVID-19合并中重度ARDS(柏林定义)患者,因相关研究发表提前终止,未达计划样本量350例。干预组给予地塞米松20mg静脉注射每日1次×5天,继以10mg每日1次×5天或至ICU出院,联合标准治疗(n=151);对照组仅标准治疗(n=148)。主要终点28天内无通气天数:地塞米松组平均6.6天(95%CI 5.0-8.2)vs 对照组4.0天(95%CI 2.9-5.4),差异2.26天(95%CI 0.2-4.38,P=0.04)。第7天SOFA评分地塞米松组6.1(95%CI 5.5-6.7)vs 对照组7.5(95%CI 6.9-8.1),差异-1.16(95%CI -1.94至-0.38,P=0.004)。28天全因死亡率、28天内无ICU天数、28天内机械通气时长、第15天6点序贯量表评分等预设次要终点无显著差异。
要点
- 地塞米松组28天内无通气天数平均6.6天(95%CI 5.0-8.2),对照组4.0天(95%CI 2.9-5.4),差异2.26天(95%CI 0.2-4.38,P=0.04)。
- 第7天SOFA评分地塞米松组平均6.1(95%CI 5.5-6.7)vs 对照组7.5(95%CI 6.9-8.1),差异-1.16(95%CI -1.94至-0.38,P=0.004)。
- 28天全因死亡率、28天内无ICU天数、28天内机械通气时长、第15天6点序贯量表评分无显著差异。
- 继发感染:地塞米松组33例(21.9%)vs 对照组43例(29.1%);需胰岛素控制血糖:47例(31.1%)vs 42例(28.3%);其他严重不良事件:5例(3.3%)vs 9例(6.1%)。
适用人群与场景
- 纳入标准:COVID-19合并中重度ARDS,符合柏林定义;年龄均值(标准差)61(14)岁,女性37%。
- 场景:巴西41个ICU,2020年4月17日至6月23日入组,最终随访至2020年7月21日完成。
诊断标准与关键阈值
- ARDS诊断依据柏林定义,病情为中重度。
处置流程与药物剂量
- 地塞米松组:地塞米松20mg静脉注射每日1次×5天,继以10mg每日1次×5天或至ICU出院,联合标准治疗。
- 对照组:仅标准治疗。
研究设计与关键结果
- 研究类型:多中心、随机、开放标签临床试验;41个ICU;样本量299例(地塞米松组n=151,标准治疗组n=148);因相关研究发表提前终止,未达计划样本量350例。
- 主要终点28天内无通气天数:地塞米松组平均6.6天(95%CI 5.0-8.2)vs 标准治疗组4.0天(95%CI 2.9-5.4),差异2.26天(95%CI 0.2-4.38,P=0.04)。
- 第7天SOFA评分:地塞米松组平均6.1(95%CI 5.5-6.7)vs 标准治疗组7.5(95%CI 6.9-8.1),差异-1.16(95%CI -1.94至-0.38,P=0.004)。
- 预设次要终点28天全因死亡率、28天内无ICU天数、28天内机械通气时长、第15天6点序贯量表评分:无显著差异。
- 不良事件:继发感染地塞米松组33例(21.9%)vs 标准治疗组43例(29.1%);需胰岛素控制血糖47例(31.1%)vs 42例(28.3%);其他严重不良事件5例(3.3%)vs 9例(6.1%)。
证据类型、等级与局限
- 证据类型:多中心随机开放标签临床试验(RCT)。
- 试验提前终止,未达计划样本量350例。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在COVID-19合并中重度ARDS的ICU患者中,静脉地塞米松联合标准治疗较单纯标准治疗可增加28天内无通气天数(差异2.26天,95%CI 0.2-4.38)。
- 该研究未显示28天全因死亡率、28天内无ICU天数、28天内机械通气时长或第15天6点序贯量表评分有显著差异。
指南或共识出处
- CoDEX随机临床试验,ClinicalTrials.gov标识NCT04327401。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) is associated with substantial mortality and use of health care resources. Dexamethasone use might attenuate lung injury in these patients.
OBJECTIVE: To determine whether intravenous dexamethasone increases the number of ventilator-free days among patients with COVID-19-associated ARDS.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, open-label, clinical trial conducted in 41 intensive care units (ICUs) in Brazil. Patients with COVID-19 and moderate to severe ARDS, according to the Berlin definition, were enrolled from April 17 to June 23, 2020. Final follow-up was completed on July 21, 2020. The trial was stopped early following publication of a related study before reaching the planned sample size of 350 patients.
INTERVENTIONS: Twenty mg of dexamethasone intravenously daily for 5 days, 10 mg of dexamethasone daily for 5 days or until ICU discharge, plus standard care (n =151) or standard care alone (n = 148).
MAIN OUTCOMES AND MEASURES: The primary outcome was ventilator-free days during the first 28 days, defined as being alive and free from mechanical ventilation. Secondary outcomes were all-cause mortality at 28 days, clinical status of patients at day 15 using a 6-point ordinal scale (ranging from 1, not hospitalized to 6, death), ICU-free days during the first 28 days, mechanical ventilation duration at 28 days, and Sequential Organ Failure Assessment (SOFA) scores (range, 0-24, with higher scores indicating greater organ dysfunction) at 48 hours, 72 hours, and 7 days.
RESULTS: A total of 299 patients (mean [SD] age, 61 [14] years; 37% women) were enrolled and all completed follow-up. Patients randomized to the dexamethasone group had a mean 6.6 ventilator-free days (95% CI, 5.0-8.2) during the first 28 days vs 4.0 ventilator-free days (95% CI, 2.9-5.4) in the standard care group (difference, 2.26; 95% CI, 0.2-4.38; P = .04). At 7 days, patients in the dexamethasone group had a mean SOFA score of 6.1 (95% CI, 5.5-6.7) vs 7.5 (95% CI, 6.9-8.1) in the standard care group (difference, -1.16; 95% CI, -1.94 to -0.38; P = .004). There was no significant difference in the prespecified secondary outcomes of all-cause mortality at 28 days, ICU-free days during the first 28 days, mechanical ventilation duration at 28 days, or the 6-point ordinal scale at 15 days. Thirty-three patients (21.9%) in the dexamethasone group vs 43 (29.1%) in the standard care group experienced secondary infections, 47 (31.1%) vs 42 (28.3%) needed insulin for glucose control, and 5 (3.3%) vs 9 (6.1%) experienced other serious adverse events.
CONCLUSIONS AND RELEVANCE: Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days (days alive and free of mechanical ventilation) over 28 days.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04327401.
参考来源
- Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020. PMID: 32876695. doi:10.1001/jama.2020.17021
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。